Post-discharge Malaria Chemoprevention Implementation Trial in Benin

Summary

The proposed research aims to conduct implementation trials in Benin, co-designed with national stakeholders, to evaluate different delivery strategies for optimizing health system delivery of post-discharge malaria chemoprevention (PDMC) drugs and adherence to PDMC. This chemoprevention strategy is effective in reducing hospital readmissions and deaths after discharge. However, there is no clear delivery platform for PDMC, and adherence to the 3-day dosing regimen, provided monthly three times after discharge, is a potential limitation. The current trial will provide evidence-based data on acceptability, feasibility, and cost-effectiveness to aid decision-makers. The evidence generated will be used to support the effective implementation and scale-up of PDMC in high malaria-endemic areas such as Benin.

Conditions

• Severe Malaria
• Severe Anaemia

Interventions

OTHER

Adherence support strategy A

Community health worker (CHW) support through monthly home visits to remind the caregiver to administrate the PDMC drugs

OTHER

Adherence support strategy B

SMS/phone reminders from the qualified community health officers (ASCQ) to the community health workers (CHW) to administrate the PDMC drugs

OTHER

Control

No reminders

Sponsors & Collaborators

• Liverpool School of Tropical Medicine

  collaborator OTHER

• Kenya Medical Research Institute

  collaborator OTHER

• Epicentre, Paris, France and Mbarara University of Science and Technology, Faculty of Medicine, Mbarara, Uganda

  collaborator OTHER

• Institut de Recherche pour le Developpement

  collaborator OTHER_GOV

• Training Research Unit of Excellence, Blantyre, Malawia

  collaborator UNKNOWN

• Centres for Disease Control and Prevention, Kenya.

  collaborator OTHER

• Institut de Recherche Clinique du Benin

  lead OTHER

Principal Investigators

• Jenny Hill, MSc, PhD · Liverpool School of Tropical Medicine

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Max Age

9 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-07-02

Primary Completion

2026-06-30

Completion

2026-12-31

Countries

• Benin

Study Locations